Significance of chemokines and activated platelets in patients with diabetes

Clin Exp Immunol. 2000 Sep;121(3):437-43. doi: 10.1046/j.1365-2249.2000.01324.x.

Abstract

Levels of platelet-derived microparticles (PMPs), platelet activation markers (P-selectin expressed on, or annexin V binding to, platelets (plt:P-selectin or plt:annexin V, respectively)), chemokines (IL-8, monocyte chemotactic peptide-1 (MCP-1), and regulated on activation normally T-cell expressed and secreted (RANTES)), and soluble P- and E-selectins were compared in peripheral blood from diabetic and control patients in order to develop a better understanding of their potential contribution to diabetic vascular complications. Significant increases were found for PMPs, plt:P-selectin, MCP-1, RANTES and soluble P- and E-selectins in diabetic individuals, whereas IL-8 levels were similar. Furthermore, after ticlopidine treatment, most of these factors receded to baseline levels observed in non-diabetic patients. Our findings indicate that ticlopidine might be able to prevent or reduce vascular complications in diabetic patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Annexin A5 / blood
  • Blood Platelets / immunology
  • Blood Platelets / metabolism
  • Case-Control Studies
  • Chemokine CCL2 / blood
  • Chemokine CCL5 / blood
  • Chemokines / blood*
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / immunology*
  • Diabetic Angiopathies / prevention & control
  • E-Selectin / blood
  • Female
  • Humans
  • Interleukin-8 / blood
  • Male
  • Middle Aged
  • P-Selectin / blood
  • Platelet Activation*
  • Platelet Aggregation Inhibitors / pharmacology
  • Ticlopidine / pharmacology

Substances

  • Annexin A5
  • Chemokine CCL2
  • Chemokine CCL5
  • Chemokines
  • E-Selectin
  • Interleukin-8
  • P-Selectin
  • Platelet Aggregation Inhibitors
  • Ticlopidine